Video
TCT 2017: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER 2A and SAPIEN 3 Cost-effectiveness
09:22
Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis
Video
TCT 2017: Dr. C. Michael Gibson talks with Dr. David Cohen about PARTNER 2A and SAPIEN 3 Cost-effectiveness
Cost-effectiveness of TAVR vs SAVR in Intermediate-Risk Patients With Aortic Stenosis
